Brand name : UZEL tablet 25mg
Active ingredient: Calcium folinate
Dosage form: tablet, light yellowish white; (Diameter 8.0mm, thickness 3.5mm)
Print on wrapping: （front）TC447 25mg,
（back）TC447 25mg
Effects of this medicine
This medicine is a reduced folic acid formulation which has no antitumor effect by itself.
The concomitant use of UFT (tegafur-uracil) and UZEL boosts the effectiveness of antitumor effect of UFT (folinate, tegafur-uracil therapy).
This folinate / tegafur-uracil therapy can be expected to reduce tumor size and alleviate symptoms.
It is commonly used to treat colorectal cancer.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you ever experienced any allergic reaction (itch, rash etc.) to any medicine. If you present a condition indicative of bone marrow suppression (including leucopenia). If you have diarrhea. If you have an infection. If you have hepatic dysfunction or a history of hepatic dysfunction. If you have renal dysfunction. If you have a heart disease or a history of heart disease. If you have gastrointestinal ulcers or hemorrhage. If you have diabetes or varicella. If you are having radiotherapy. If you have been previously treated with other chemotherapy medicines.
•If you are using TS-1, fluoropyrimidine anticancer drug, currently or within the last 7 days.
•If you are pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•General dosage regimen (for adults): UZEL is administered 1 tablet (equivalent to 25mg of Calcium Folinate) 3 times daily (at an interval of approximately 8 hours) together with UFT. Administration should be withheld during one hour before or after meal. Repeat a course of 28 consecutive days (4 weeks) followed by a 7-day (1 week) rest period. Be sure to follow the dosage instructions.
•UZEL must not be combined with TS-1, fluoropyrimidine anticancer drug. A minimum washout period of 7 days must be provided when UZEL is used after withdrawal of TS-1.
•Proceed with the prescribed schedule of medication starting from the next dose. DO NOT take a double dose to make up for the missed dose.
•If you took too much of this medicine (more than ordered), check with your doctor/pharmacist.
•Do not change your dose and schedule of your chemotherapy without the instructions of your doctor.
Precautions while taking this medicine
•During the treatment, laboratory tests (hematological, liver and renal function tests) are performed regularly to detect asymptomatic side effects as early as possible. Be sure to consult your doctor.
Possible adverse reactions to this medicine
Common side effects are reported as below. If any of them occurs, check with your doctor/pharmacist: diarrhea, stomatitis, anorexia, nausea, vomiting, tasteabnormality, tiredness, pigmentation, rash, itch, abdominal pain.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•Bleeding tendency, tiredness, sore throat, fever[bone marrow suppression]
•Yellowing of the skin, tiredness, yellowing of the whites of the eyes, anorexia[severe hepatic dysfunction]
•Diarrhea, severe abdominal pain[severe enteritis]
•Unstableness, forgetfulness, trouble speaking[psychoneurologic disorders including leukoencephalopathy or other symptoms]
•Olfactory disturbance[anosmia]
•Difficult breathing, fever, dry cough[interstitial pneumonia]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Storage conditions and other information
•Keep the medicine out of the reach of babies, infants and children. Store away from direct light, heat, and humidity.
•If you have any left-over medicine, be sure to discard it.
TAIHO Pharmaceutical Co.,LTD.Internal
Revised: 10/2008
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
http://www.kegg.jp/medicus-bin/japic_med?japic_code=00049739 |
